Adaptimmune Therapeutics
(NASDAQ:ADAP)
$1.56
-0.02[-1.27%]
At close: Mar 28
$1.56
0[0.00%]
After Hours: 7:37PM EDT
Consensus Rating1
Buy
Highest Price Target1
$10.00
Lowest Price Target1
$1.00
Consensus Price Target1
$4.94

Adaptimmune Therapeutics Stock (NASDAQ:ADAP), Analyst Ratings, Price Targets, Predictions

Adaptimmune Therapeutics PLC has a consensus price target of $4.94, established from looking at the 20 latest analyst ratings. The last 3 analyst ratings were released from Barclays, EF Hutton, and EF Hutton on August 10, 2023, August 10, 2023, and June 5, 2023. With an average price target of $7 between Barclays, EF Hutton, and EF Hutton, there's an implied 348.72% upside for Adaptimmune Therapeutics PLC from these 3 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Feb
0
0
0
0
0
Jan
0
0
0
0
0
Dec 23
0
0
0
0
0
Nov 23
0
0
0
0
0
Oct 23
0
0
0
0
0
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Barclays
EF Hutton
Guggenheim
Wells Fargo
Mizuho

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Adaptimmune Therapeutics

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
08/10/2023ADAPBuy Now
Adaptimmune Therapeutics
$1.56-35.9%Barclays
Peter Lawson
$2 → $1MaintainsUnderweightGet Alert
08/10/2023ADAPBuy Now
Adaptimmune Therapeutics
$1.56541.03%EF Hutton
Tony Butler
→ $10ReiteratesBuy → BuyGet Alert
06/05/2023ADAPBuy Now
Adaptimmune Therapeutics
$1.56541.03%EF Hutton
Tony Butler
→ $10ReiteratesBuy → BuyGet Alert
06/02/2023ADAPBuy Now
Adaptimmune Therapeutics
$1.56541.03%EF Hutton
Tony Butler
→ $10Reiterates → BuyGet Alert
05/26/2023ADAPBuy Now
Adaptimmune Therapeutics
$1.56541.03%EF Hutton
Tony Butler
→ $10Reiterates → BuyGet Alert
04/17/2023ADAPBuy Now
Adaptimmune Therapeutics
$1.56541.03%EF Hutton
Tony Butler
→ $10Reiterates → BuyGet Alert
04/11/2023ADAPBuy Now
Adaptimmune Therapeutics
$1.56541.03%EF Hutton
Tony Butler
→ $10Reiterates → BuyGet Alert
03/06/2023ADAPBuy Now
Adaptimmune Therapeutics
$1.56541.03%EF Hutton
Tony Butler
→ $10Reiterates → BuyGet Alert
01/05/2023ADAPBuy Now
Adaptimmune Therapeutics
$1.56541.03%EF Hutton
Tony Butler
→ $10Initiates → BuyGet Alert
01/03/2023ADAPBuy Now
Adaptimmune Therapeutics
$1.56220.51%Guggenheim
Michael Schmidt
→ $5UpgradeNeutral → BuyGet Alert
11/14/2022ADAPBuy Now
Adaptimmune Therapeutics
$1.5692.31%Wells Fargo
Yanan Zhu
$1.5 → $3MaintainsEqual-WeightGet Alert
11/09/2022ADAPBuy Now
Adaptimmune Therapeutics
$1.56476.92%Mizuho
Mara Goldstein
→ $9UpgradeNeutral → BuyGet Alert
10/04/2022ADAPBuy Now
Adaptimmune Therapeutics
$1.56-3.85%Wells Fargo
Nick Abbott
$7 → $1.5MaintainsEqual-WeightGet Alert
05/09/2022ADAPBuy Now
Adaptimmune Therapeutics
$1.5692.31%SVB Leerink
Jonathan Chang
$2 → $3MaintainsMarket PerformGet Alert
03/15/2022ADAPBuy Now
Adaptimmune Therapeutics
$1.5692.31%SVB Leerink
Jonathan Chang
$7 → $3MaintainsMarket PerformGet Alert
09/22/2021ADAPBuy Now
Adaptimmune Therapeutics
$1.56348.72%Wells FargoMaintainsEqual-WeightGet Alert
09/13/2021ADAPBuy Now
Adaptimmune Therapeutics
$1.56348.72%SVB Leerink
Jonathan Chang
MaintainsMarket PerformGet Alert
09/07/2021ADAPBuy Now
Adaptimmune Therapeutics
$1.56284.62%SVB Leerink
Jonathan Chang
MaintainsMarket PerformGet Alert
08/10/2021ADAPBuy Now
Adaptimmune Therapeutics
$1.56220.51%SVB Leerink
Jonathan Chang
MaintainsMarket PerformGet Alert

FAQ

Q

What is the target price for Adaptimmune Therapeutics (ADAP)?

A

The latest price target for Adaptimmune Therapeutics (NASDAQ: ADAP) was reported by Barclays on August 10, 2023. The analyst firm set a price target for $1.00 expecting ADAP to fall to within 12 months (a possible -35.90% downside). 7 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Adaptimmune Therapeutics (ADAP)?

A

The latest analyst rating for Adaptimmune Therapeutics (NASDAQ: ADAP) was provided by Barclays, and Adaptimmune Therapeutics maintained their underweight rating.

Q

When was the last upgrade for Adaptimmune Therapeutics (ADAP)?

A

The last upgrade for Adaptimmune Therapeutics PLC happened on January 3, 2023 when Guggenheim raised their price target to $5. Guggenheim previously had a neutral for Adaptimmune Therapeutics PLC.

Q

When was the last downgrade for Adaptimmune Therapeutics (ADAP)?

A

There is no last downgrade for Adaptimmune Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Adaptimmune Therapeutics (ADAP)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adaptimmune Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adaptimmune Therapeutics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

Q

Is the Analyst Rating Adaptimmune Therapeutics (ADAP) correct?

A

While ratings are subjective and will change, the latest Adaptimmune Therapeutics (ADAP) rating was a maintained with a price target of $2.00 to $1.00. The current price Adaptimmune Therapeutics (ADAP) is trading at is $1.56, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch